[go: up one dir, main page]

PE128699A1 - Formula de liberacion prolongada que contiene venlafaxina - Google Patents

Formula de liberacion prolongada que contiene venlafaxina

Info

Publication number
PE128699A1
PE128699A1 PE1998001045A PE00104598A PE128699A1 PE 128699 A1 PE128699 A1 PE 128699A1 PE 1998001045 A PE1998001045 A PE 1998001045A PE 00104598 A PE00104598 A PE 00104598A PE 128699 A1 PE128699 A1 PE 128699A1
Authority
PE
Peru
Prior art keywords
refers
prolonged release
formula containing
release formula
venlafaxine
Prior art date
Application number
PE1998001045A
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Clifton Clark
Stephen A White
John Ulrick Lamer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE128699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE128699A1 publication Critical patent/PE128699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A FORMULAS ENCAPSULADAS DE LIBERACION PROLONGADA QUE COMPRENDE UN NUCLEO ESFEROIDE QUE CONTIENE ENTRE 30% Y 40% DE CLORHIDRATO DE VENLAFAXINA Y CELULOSA MICROCRISTALINA, LIBRE DE HIDROXIPROPILMETILCELULOSA; TAMBIEN SE REFIERE A UN NUCLEO ESFEROIDE RECUBIERTO CON 80% A 90% DE ETILCELULOSA Y CON 10% A 20% DE HIDROXIPROPILMETILCELULOSA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL USO DE ESTA FORMULACION UNA VEZ AL DIA, PUEDE REDUCIR LA INCIDENCIA DE NAUSEAS Y EMESIS ASOCIADA CON LA ADMINISTRACION DOSIS DIARIAS MULTIPLES
PE1998001045A 1997-11-05 1998-11-04 Formula de liberacion prolongada que contiene venlafaxina PE128699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
PE128699A1 true PE128699A1 (es) 2000-01-06

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001045A PE128699A1 (es) 1997-11-05 1998-11-04 Formula de liberacion prolongada que contiene venlafaxina

Country Status (38)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514612A (en) * 1999-04-06 2004-01-30 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
JP2003500348A (ja) * 1999-05-20 2003-01-07 エラン コーポレーシヨン ピーエルシー 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
AR039163A1 (es) 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
EP1487429A2 (en) * 2002-03-28 2004-12-22 Synthon B.V. Compositions of venlafaxine base
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
PT1502587E (pt) * 2003-07-30 2007-01-31 Pharmathen Sa Formulação de libertação prolongada para cloridrato de venlafaxina
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
RU2340331C2 (ru) 2004-02-04 2008-12-10 Алембик Лимитед Форма пролонгированного высвобождения венлафаксина гидрохлорида
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
NO20002126L (no) 2000-05-04
EP1028718A2 (en) 2000-08-23
UY25692A1 (es) 2000-03-31
DE69813602T2 (de) 2003-11-06
WO1999022724A3 (en) 1999-07-22
PA8462501A1 (es) 2000-05-24
HU225238B1 (en) 2006-08-28
NZ504460A (en) 2003-01-31
AU747978B2 (en) 2002-05-30
KR20010031797A (ko) 2001-04-16
TW555568B (en) 2003-10-01
NO20002126D0 (no) 2000-04-26
DE69813602D1 (de) 2003-05-22
HRP20000213B1 (en) 2004-04-30
CZ20001659A3 (cs) 2001-10-17
CL2004001705A1 (es) 2005-06-03
UA77145C2 (en) 2006-11-15
GEP20043198B (en) 2004-03-25
CN1278165A (zh) 2000-12-27
CA2305242A1 (en) 1999-05-14
AU1300399A (en) 1999-05-24
CO5011060A1 (es) 2001-02-28
BR9813179A (pt) 2000-08-22
EP1028718B1 (en) 2003-04-16
HUP0004287A2 (hu) 2002-04-29
IL135457A0 (en) 2001-05-20
DK1028718T3 (da) 2003-07-28
EE04577B1 (et) 2006-02-15
ES2196620T3 (es) 2003-12-16
JP2001521892A (ja) 2001-11-13
PT1028718E (pt) 2003-07-31
PL341141A1 (en) 2001-03-26
HRP20000213A2 (en) 2000-12-31
HK1029056A1 (en) 2001-03-23
TR200001232T2 (tr) 2000-12-21
ZA9810081B (en) 2000-05-04
AR014012A1 (es) 2001-01-31
MA24691A1 (fr) 1999-07-01
EE200000212A (et) 2001-04-16
UY25234A1 (es) 2000-12-29
SK6472000A3 (en) 2000-11-07
HUP0004287A3 (en) 2002-05-28
SV1998000131A (es) 1999-11-18
ATE237320T1 (de) 2003-05-15
BG104397A (en) 2001-02-28
ID26317A (id) 2000-12-14
EA200000487A1 (ru) 2000-10-30
WO1999022724A2 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
PE128699A1 (es) Formula de liberacion prolongada que contiene venlafaxina
AR006519A1 (es) Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada
CO4750836A1 (es) Nuevos medicamentos y utilizacion (1-metiletil)-8-azoniabiciclo-[3.2.1]octnao y su uso en pre- paraciones medicas
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
IL115046A0 (en) A sprayable film-forming preparation for application to plants and the uses thereof
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
NO954952L (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
MX9204212A (es) Preparado de combinacion farmaceutico.
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
ES2175086T3 (es) Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina.
ECSP982704A (es) Formula de liberacion prolongada
NO952308D0 (no) Anvendelse av ruluzoler som radiorestaurator
ECSP972046A (es) Formula de liberacion prolongada
RU94023370A (ru) Анальгезирующее средство

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed